Kangstem Biotech (A217730) Stock Overview
A biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
A217730 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Kangstem Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,145.00 |
| 52 Week High | ₩2,530.00 |
| 52 Week Low | ₩1,080.00 |
| Beta | 0.84 |
| 1 Month Change | -0.69% |
| 3 Month Change | 44.54% |
| 1 Year Change | 10.00% |
| 3 Year Change | -27.66% |
| 5 Year Change | -70.29% |
| Change since IPO | -77.08% |
Recent News & Updates
Recent updates
Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?
Sep 24
Is Kangstem Biotech (KOSDAQ:217730) Using Debt Sensibly?
May 24Investors Don't See Light At End Of Kangstem Biotech Co., Ltd.'s (KOSDAQ:217730) Tunnel
Mar 06Is Kangstem Biotech (KOSDAQ:217730) Weighed On By Its Debt Load?
Feb 17Would Shareholders Who Purchased Kang Stem Biotech's (KOSDAQ:217730) Stock Three Years Be Happy With The Share price Today?
Dec 26Shareholder Returns
| A217730 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 1.7% | 3.5% | 5.9% |
| 1Y | 10.0% | 49.6% | 101.6% |
Return vs Industry: A217730 underperformed the KR Biotechs industry which returned 49.6% over the past year.
Return vs Market: A217730 underperformed the KR Market which returned 101.6% over the past year.
Price Volatility
| A217730 volatility | |
|---|---|
| A217730 Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in KR Market | 12.6% |
| 10% least volatile stocks in KR Market | 2.8% |
Stable Share Price: A217730 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A217730's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 97 | Jong-Cheon Na | www.kangstem.com |
Kangstem Biotech Co., Ltd. a biopharmaceutical company, develops stem cell therapeutic products for rare and incurable diseases. The company's stem cell therapy products include Furestem-AD for treatment of subacute and chronic atopic dermatitis; Furestem-RA to treat rheumatoid arthritis; and Furestem-CD for treatment of active crohn’s disease. It also provides stem cell conditioned media, such as umbilical cord blood-derived stem cell conditioned media that includes epidermal, vascular endothelium, keratinocyte, hepatocyte, transforming, and platelet-derived growth factors, as well as growth and differentiation factor 11, and Fibroblast growth factor 2 for skin growth and regeneration.
Kangstem Biotech Co., Ltd. Fundamentals Summary
| A217730 fundamental statistics | |
|---|---|
| Market cap | ₩206.45b |
| Earnings (TTM) | -₩10.09b |
| Revenue (TTM) | ₩12.77b |
Is A217730 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A217730 income statement (TTM) | |
|---|---|
| Revenue | ₩12.77b |
| Cost of Revenue | ₩11.00b |
| Gross Profit | ₩1.78b |
| Other Expenses | ₩11.87b |
| Earnings | -₩10.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -107.27 |
| Gross Margin | 13.91% |
| Net Profit Margin | -78.98% |
| Debt/Equity Ratio | 14.6% |
How did A217730 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/02 16:31 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kangstem Biotech Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.